Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: Comparison between preparation with thyroid hormone withdrawal and thyrogen

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 8, 2008, Pages 1457-1463

  Borget, I ^a   Remy, H ^a   Chevalier, J ^a   Ricard, M ^a   Allyn, M ^b   Schlumberger, M ^a   De Pouvourville, G ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b GENZYME CORPORATION   (United States)

^c ESSEC BUSINESS SCHOOL   (France)

Author keywords

Cost; Hospital stay; Radioiodine ablation; rhTSH; Thyroid carcinoma; Thyroid hormone withdrawal

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROID HORMONE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH ECONOMICS; HORMONAL THERAPY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; SIMULATION; THYROID CANCER; THYROID HORMONE WITHDRAWAL THERAPY;

CASE-CONTROL STUDIES; FEMALE; FRANCE; HEALTH CARE COSTS; HUMANS; IODINE RADIOISOTOPES; LENGTH OF STAY; MALE; MIDDLE AGED; THYROID NEOPLASMS; THYROTROPIN;

EID: 48149093877     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0754-9     Document Type: Article

References (21)

1. CF Eustatia-Rutten JW Smit JA Romijn EP van der Kleij-Corssmit AM Pereira MP Stokkel 2004 Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis Clin Endocrinol (Oxf). 61 61 74
2. F Pacini M Schlumberger H Dralle R Elisei JW Smit W Wiersinga 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol. 154 787 803
3. DS Cooper GM Doherty BR Haugen RT Kloos SL Lee SJ Mandel 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid. 16 109 142
4. F Pacini PW Ladenson M Schlumberger A Driedger M Luster RT Kloos 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study J Clin Endocrinol Metab. 91 926 932
5. PR Schroeder BR Haugen F Pacini C Reiners M Schlumberger SI Sherman 2006 A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal J Clin Endocrinol Metab. 91 878 884
6. M Luster F Lippi B Jarzab P Perros M Lassmann C Reiners 2005 rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review Endocr Relat Cancer. 12 49 64
7. F Lippi M Capezzone F Angelini D Taddei E Molinaro A Pinchera 2001 Radioiodine treatment of metastatic differentiated thyroid cancer in patients on l-thyroxine, using recombinant human TSH Eur J Endocrinol. 144 5 11
8. M Luster M Lassmann H Haenscheid U Michalowski C Incerti C Reiners 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma J Clin Endocrinol Metab. 85 3640 3645
9. RJ Robbins RM Tuttle RN Sharaf SM Larson HK Robbins RA Ghossein 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma J Clin Endocrinol Metab. 86 619 625
10. 131I Nucl Med Commun. 12 485 495
11. M Luster SI Sherman MC Skarulis JR Reynolds M Lassmann H Hanscheid 2003 Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma Eur J Nucl Med Mol Imaging. 30 1371 1377
12. C Menzel WT Kranert N Dobert M Diehl T Fietz N Hamscho 2003 rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I J Nucl Med. 44 1065 1068
13. 131I J Nucl Med. 44 898 903
14. H Hanscheid M Lassmann M Luster SR Thomas F Pacini C Ceccarelli 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal J Nucl Med. 47 648 54
15. HM Park OW Perkins JW Edmondson RB Schnute A Manatunga 1994 Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131 Thyroid. 4 49 54
16. P Mernagh S Campbell M Dietlein M Luster E Mazzaferri AR Weston 2006 Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective Eur J Endocrinol. 155 405 414
17. G Berg G Lindstedt M Suurkula S Jansson 2002 Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone J Endocrinol Invest. 25 44 52
18. I Borget C Corone M Nocaudie M Allyn S Iacobelli M Schlumberger 2007 Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal Eur J Endocrinol. 156 531 538
19. 131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur J Endocrinol. 153 651 659
20. E Polverejan JC Gardiner CJ Bradley M Holmes-Rovner D Rovner 2003 Estimating mean hospital cost as a function of length of stay and patient characteristics Health Econ. 12 935 947
21. PA Taheri DA Butz LJ Greenfield 2000 Length of stay has minimal impact on the cost of hospital admission J Am Coll Surg. 191 123 130